<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Oncogenic Ras triggers hyperproliferation and impairs polarized colonic morphogenesis by autocrine ErbB3 signaling</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-07-18">July 18, 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Yvonne</forename><surname>Möller</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Cell Biology and Immunology</orgName>
								<orgName type="institution">University of Stuttgart</orgName>
								<address>
									<settlement>Stuttgart</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Markus</forename><surname>Morkel</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="laboratory">Laboratory of Molecular Tumor Pathology and Systems Biology</orgName>
								<orgName type="institution">Charité Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jens</forename><surname>Schmid</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology</orgName>
								<orgName type="institution">University of Tübingen</orgName>
								<address>
									<settlement>Stuttgart</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sven</forename><surname>Beyes</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Cell Biology and Immunology</orgName>
								<orgName type="institution">University of Stuttgart</orgName>
								<address>
									<settlement>Stuttgart</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Janina</forename><surname>Hendrick</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Cell Biology and Immunology</orgName>
								<orgName type="institution">University of Stuttgart</orgName>
								<address>
									<settlement>Stuttgart</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michaela</forename><surname>Strotbek</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Cell Biology and Immunology</orgName>
								<orgName type="institution">University of Stuttgart</orgName>
								<address>
									<settlement>Stuttgart</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pamela</forename><surname>Riemer</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="laboratory">Laboratory of Molecular Tumor Pathology and Systems Biology</orgName>
								<orgName type="institution">Charité Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">DKTK</orgName>
								<orgName type="institution">German Cancer Consortium</orgName>
								<address>
									<addrLine>Partner site Charité</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Simone</forename><surname>Schmid</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Cell Biology and Immunology</orgName>
								<orgName type="institution">University of Stuttgart</orgName>
								<address>
									<settlement>Stuttgart</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lisa</forename><forename type="middle">C</forename><surname>Schmitt</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Cell Biology and Immunology</orgName>
								<orgName type="institution">University of Stuttgart</orgName>
								<address>
									<settlement>Stuttgart</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Roland</forename><surname>Kontermann</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Cell Biology and Immunology</orgName>
								<orgName type="institution">University of Stuttgart</orgName>
								<address>
									<settlement>Stuttgart</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Stuttgart Research Center Systems Biology (SRCSB)</orgName>
								<orgName type="institution">University of Stuttgart</orgName>
								<address>
									<settlement>Stuttgart</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><surname>Mürdter</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology</orgName>
								<orgName type="institution">University of Tübingen</orgName>
								<address>
									<settlement>Stuttgart</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Matthias</forename><surname>Schwab</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology</orgName>
								<orgName type="institution">University of Tübingen</orgName>
								<address>
									<settlement>Stuttgart</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department">Department of Clinical Pharmacology</orgName>
								<orgName type="institution">University Hospital</orgName>
								<address>
									<settlement>Tübingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">Department of Biochemistry and Pharmacy</orgName>
								<orgName type="institution">University of Tübingen</orgName>
								<address>
									<settlement>Tübingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christine</forename><surname>Sers</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="laboratory">Laboratory of Molecular Tumor Pathology and Systems Biology</orgName>
								<orgName type="institution">Charité Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">DKTK</orgName>
								<orgName type="institution">German Cancer Consortium</orgName>
								<address>
									<addrLine>Partner site Charité</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Monilola</forename><forename type="middle">A</forename><surname>Olayioye</surname></persName>
							<email>monilola.olayioye@izi.uni-stuttgart.de</email>
							<affiliation key="aff0">
								<orgName type="department">Institute of Cell Biology and Immunology</orgName>
								<orgName type="institution">University of Stuttgart</orgName>
								<address>
									<settlement>Stuttgart</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Stuttgart Research Center Systems Biology (SRCSB)</orgName>
								<orgName type="institution">University of Stuttgart</orgName>
								<address>
									<settlement>Stuttgart</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="department" key="dep1">Institute of Molecular Medicine and Cell Research</orgName>
								<orgName type="department" key="dep2">Faculty of Biology</orgName>
								<orgName type="institution">Albert-Ludwigs-University</orgName>
								<address>
									<settlement>Freiburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Oncogenic Ras triggers hyperproliferation and impairs polarized colonic morphogenesis by autocrine ErbB3 signaling</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-07-18">July 18, 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">1AF4E4E98D2151EDA46F2EB9AD61B812</idno>
					<note type="submission">Received: January 31, 2016 Accepted: July 09, 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:19+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>oncogenic Ras</term>
					<term>ErbB3/HER3</term>
					<term>3D culture</term>
					<term>intestinal organoids</term>
					<term>apical-basolateral polarity</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Here we study the effects of inducible oncogenic K-Ras (G12V) expression on the polarized morphogenesis of colonic epithelial cells.</s><s>We provide evidence that the autocrine production of heregulins, ligands for the ErbB3 receptor tyrosine kinase, is responsible for the hyperproliferation and aberrant 3D morphogenesis upon oncogenic K-Ras expression.</s><s>This is in line with results obtained in primary intestinal organoid cultures, in which exogenous heregulin is shown to interfere with normal tissue architecture.</s><s>Importantly, ErbB3 inhibition and heregulin gene silencing rescued K-Ras G12V -induced features of cell transformation.</s><s>Together with the increased ErbB3 positivity detected in human high-grade primary colorectal cancers, our findings provide support for an autocrine signaling loop engaged by oncogenic K-Ras involving ErbB3 that contributes to the dedifferentiation of the intestinal epithelium during tumor initiation and progression.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>Colorectal cancer (CRC) originates from the neoplastic transformation of epithelial cells, progressing from an adenoma to a carcinoma stage <ref type="bibr" target="#b0">[1]</ref>.</s><s>In approximately 40% of CRC cases, somatic missense mutations in codons 12, 13, or 61 of K-Ras impair its GTPase activity, resulting in constitutive activation of the protein <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref>.</s><s>In general, this is thought to uncouple Ras activation from extracellular signaling cues such as growth factor binding to receptor tyrosine kinases (RTKs), thereby conferring growth factor independence to mutant cells.</s><s>Therefore, tumors with mutated K-Ras fail to respond to Cetuximab and Panitumumab, monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR/ErbB1).</s><s>Anti-ErbB1 therapy is thus restricted to patients with no detectable K-Ras mutation and no targeted therapies are currently available for patients with K-Ras mutant CRC <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b4">5]</ref>.</s></p><p><s>ErbB1 belongs to the ErbB family of RTKs, which further comprises ErbB2/HER2, ErbB3/HER3 and ErbB4/ HER4.</s><s>Upon binding of specific peptide ligands the receptors homo-and heterodimerize, triggering tyrosine phosphorylation of the cytoplasmic tails and activation of downstream signaling.</s><s>This includes activation of the Ras proteins, and subsequently the MAPK and PI3K pathways,</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Research Paper</head><p><s>which mediate biological responses such as proliferation, invasion and survival <ref type="bibr" target="#b5">[6]</ref>.</s><s>Although ErbB2 has no direct ligand, it readily dimerizes with the other ErbB receptors due to its constitutively active conformation <ref type="bibr" target="#b6">[7]</ref>.</s><s>ErbB3 is unique in that it has an impaired kinase domain, but in a heterodimer with a signaling competent ErbB family member, ErbB3 becomes phosphorylated and can serve as a signaling platform <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b8">9]</ref>.</s><s>The presence of several consensus sites for the p85 subunit of PI3K mediates the potent induction of PI3K-Akt signaling by phosphorylated ErbB3 <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b9">10]</ref>.</s></p><p><s>ErbB receptors are activated by a variety of different peptide ligands.</s><s>Whereas EGF, TGF-α and amphiregulin bind to ErbB1, the heregulins (HRGs; also known as neuregulins) bind ErbB3 and ErbB4 <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b11">12]</ref>.</s><s>In epithelia that express both, the ligands and receptors, tight junctions separate the different subcellular membranes the receptors and cognate ligands are directed to, thereby preventing autocrine stimulation <ref type="bibr" target="#b12">[13]</ref>.</s><s>In cancer, different mechanisms can contribute to autocrine signals: firstly, cell polarity and therefore the separation between apical and basolateral membranes of epithelial cells can be compromised <ref type="bibr" target="#b13">[14]</ref>, and secondly, tumor-specific changes in gene expression can result in the complementation of cognate ligand-receptor pairs in the transformed tissue <ref type="bibr" target="#b14">[15,</ref><ref type="bibr" target="#b15">16]</ref>.</s></p><p><s>Studies in cell culture have been instrumental in delineating tumor-associated signaling pathways and genetic alterations on cellular behavior, however, classical monolayer cultures do not replicate the complex interactions of the apical and basolateral membrane compartments.</s><s>By contrast, cultivation of epithelial cells in a three-dimensional (3D) environment containing extracellular matrix (ECM) components recapitulates some of the conditions found in vivo <ref type="bibr" target="#b16">[17,</ref><ref type="bibr" target="#b17">18]</ref>.</s><s>In such culture systems the establishment and maintenance of polarized morphology can be studied and the different steps of tumor initiation and progression modeled.</s><s>More recently, the development of 3D intestinal organoid cultures derived from primary tissues has enabled the study of differentiation programs and epithelial tissue organization ex vivo <ref type="bibr" target="#b18">[19]</ref>.</s></p><p><s>Here we investigate how the acute expression of oncogenic K-Ras G12V disrupts polarized morphogenesis of colonic epithelial cells in 3D culture and identify a novel autocrine signaling loop that mediates hyperproliferation and loss of cell polarity involving the RTK ErbB3.</s><s>We moreover show that exogenous HRG addition is sufficient to mimic these effects both in Caco-2 CRC cells and in primary intestinal organoid cultures.</s><s>Our findings thus have implications for the development of anti-cancer therapies targeting the HRG-ErbB3 signaling axis in the context of K-Ras mutant CRC.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head><p><s>The human CRC cell line Caco-2 forms polarized cysts when grown in 3D matrigel cultures, recapitulating morphological features of the intestinal epithelium.</s><s>These cysts are characterized by a single epithelial cell layer with apical-basolateral polarity that surrounds a hollow lumen <ref type="bibr" target="#b19">[20]</ref>.</s><s>Doxycycline-inducible expression of oncogenic K-Ras G12V in these cells leads to the formation of hyperproliferating spherical structures, which are no longer polarized and fail to establish a central lumen (Figure <ref type="figure" target="#fig_0">1A</ref>) <ref type="bibr" target="#b20">[21,</ref><ref type="bibr" target="#b21">22]</ref>.</s><s>Quantification of the effects of K-Ras G12V expression, visualized by the bi-cistronic GFP expression, showed that the average number of cells in the midplane of the cysts doubled compared to the non-induced control and only ~15% of the cysts were scored as normal, based on morphological criteria (see methods for details) that include well-defined apical F-actin accumulation (Figure <ref type="figure" target="#fig_0">1B, 1C</ref>).</s></p><p><s>To investigate the potential contribution of the ErbB receptors to the aberrant morphogenesis and hyperproliferation induced by K-Ras G12V expression, we treated the doxycycline-containing 3D cultures with the pan-ErbB inhibitor AZD8931.</s><s>This inhibitor potently suppressed short-term ligand-induced ErbB receptor activation and downstream signaling in Caco-2 cells (Supplementary Figure <ref type="figure" target="#fig_0">S1A</ref>).</s><s>Interestingly, the abnormal morphology and hyperproliferation of K-Ras G12V -expressing Caco-2 cysts was partially restored, with almost 40% of cysts displaying polarized structures with a predominant single apical lumen (PSAL; Figure <ref type="figure" target="#fig_0">1D-1F</ref>).</s><s>Next, we recovered the cysts from the 3D cultures, and analyzed the lysates by immunoblotting.</s><s>Compared to the low basal phosphorylation in noninduced cells (-dox), K-Ras G12V expression (+dox) revealed hyperactivation of MAPK and PI3K pathways, as judged by increased phosphorylation of Erk and Akt on T202/ Y204 and T308/S473, respectively (Figure <ref type="figure" target="#fig_0">1G</ref>).</s><s>ErbB1 phosphorylation was readily detectable in both control and K-Ras G12V -expressing cells, whereas no phosphorylation was visible for ErbB2 and ErbB3.</s><s>Expression of ErbB4 was below the detection limit.</s><s>AZD8931 potently suppressed ErbB1 phosphorylation in control (-dox) and oncogenic Ras-expressing cells.</s><s>Although AZD8931 addition to the cultures three days before harvest suppressed Erk and Akt phosphorylation in the control cells, Erk and Akt phosphorylation were maintained in K-Ras G12V -expressing cells, illustrating the dominant signaling of oncogenic K-Ras with respect to the MAPK and PI3K pathways (Figure <ref type="figure" target="#fig_0">1G</ref>).</s><s>Comparable results were obtained with a second inhibitor (ErbB2-II), which also restored the morphogenetic defects in Caco-2tet Ras G12V cells (Supplementary Figure <ref type="figure" target="#fig_0">S1B</ref>, left).</s><s>This inhibitor blocked HRG-induced ErbB2 and ErbB3 activation, but had no effect on EGF-induced ErbB1 phosphorylation (Supplementary Figure <ref type="figure" target="#fig_0">S1B</ref>, right).</s></p><p><s>To identify the ErbB receptors that cooperate with K-Ras G12V signaling, we performed gene silencing experiments.</s><s>Caco-2tet K-Ras G12V cells were transfected with control siRNA (siNT) or ErbB receptor-specific siRNAs (siErbB1/2/3) and then seeded into 3D culture, followed by the induction of K-Ras G12V the next day.</s><s>Morphological analysis revealed that the cysts formed by oncogenic Ras-expressing cells depleted of ErbB1 or ErbB2 were comparable to those transfected with the siRNA control.</s><s>By contrast, upon ErbB3 depletion, the K-Ras G12V -induced defect in polarized morphogenesis was rescued, as seen by the apical accumulation of the marker atypical PKC (aPKC) and F-actin (Figure <ref type="figure" target="#fig_1">2A, 2B</ref>).</s><s>Note that K-Ras G12V expression was not altered by the siRNA transfection as judged by the GFP signal.</s><s>Additionally, in the absence of ErbB3, the hyperproliferation triggered by The percentage of cysts with PSAL from (A) was determined (n&gt;70; N=3).</s><s>C. The number of nuclei in the midplane of cysts from (A) was counted (n=25; N=3).</s><s>D. Caco-2tet K-Ras G12V cells were seeded into 3D cultures.</s><s>One day post seeding K-Ras G12V -expression was induced by dox and cultures were left untreated or treated with 200 nM AZD8931.</s><s>Two days later CTX was added.</s><s>Cultures were fixed the next day and stained with DAPI (nuclei; blue) and phalloidin (F-actin; red).</s><s>GFP is co-expressed with K-Ras G12V (green).</s><s>Shown are confocal sections of the midplane of representative cysts (scale: 20 μm).</s><s>E. The percentage of cysts with PSAL from (D) was determined (n&gt;60; N=3).</s><s>F. The number of nuclei in the midplane of cysts from (D) was counted (n=25; N=3) G. Caco-2tet K-Ras G12V cells were seeded into 3D cultures.</s><s>One day post seeding K-Ras G12V expression was induced by dox and cultures were left untreated or treated with 200 nM AZD8931.</s><s>Lysates were generated four days after seeding and analyzed by immunoblotting using the indicated antibodies (pErbB2(Tyr1248)).</s><s>Tubulin was detected as a loading control.</s><s>A representative blot is shown (N=3).</s><s>K-Ras G12V was abrogated (Figure <ref type="figure" target="#fig_1">2C</ref>), with average cell numbers in the midplane of cysts comparable to those observed in non-induced control cultures (Figure <ref type="figure" target="#fig_0">1C</ref>).</s><s>This was specific to the 3D cultures, as ErbB3 depletion did not inhibit the proliferation of Ras G12V -expressing cells grown in 2D monolayers (data not shown).</s><s>ErbB receptor knockdown was verified by immunoblotting (Figure <ref type="figure" target="#fig_1">2D</ref>) and similar results were obtained by independent siRNAs (Supplementary Figure <ref type="figure" target="#fig_1">S2A+S2B</ref>).</s><s>Analysis of downstream signaling showed no impact of ErbB3 depletion on the Ras G12V -dependent activation of Erk and Akt (Supplementary Figure <ref type="figure" target="#fig_1">S2C</ref>).</s><s>Taken together, these findings uncover a role for ErbB3 in oncogenic Rasinduced hyperproliferation and polarity loss, which were partially rescued by pharmacologic pan-ErbB receptor inhibition or specific siRNA-mediated knockdown.</s></p><p><s>To analyze the impact of different ErbB ligands on Caco-2 3D proliferation and morphogenesis, we embedded the parental cells in growth factor-reduced matrigel with low serum (2%) in the presence of the different ErbB ligands.</s><s>Stimulating effects as measured by MTT activity were detected following EGF, TGF-α, and HB-EGF addition and strongest stimulation was induced by HRG (Figure <ref type="figure" target="#fig_2">3A</ref>).</s><s>Importantly, despite effects on proliferation as seen by the increased sizes of cysts (Figure <ref type="figure" target="#fig_2">3C</ref>), apart from HRG, none of the ErbB ligands interfered with polarized cyst morphology and lumenogenesis (Figure <ref type="figure" target="#fig_2">3B, 3C</ref>).</s><s>In the presence of HRG, a significant drop in the percentage of cysts with defined apical F-actin staining and central lumens was noted (Figure <ref type="figure" target="#fig_2">3B</ref>, 3C), similar to the phenotype induced by K-Ras G12V .</s><s>Expression of aPKC and E-cadherin, which demarcate the apical and basolateral membranes, respectively, were retained in the presence of HRG, but distinct apical aPKC localization was lost (Figure <ref type="figure" target="#fig_2">3D</ref>).</s><s>To prove that HRG signaling was disrupting apical-basolateral polarity and not simply inducing hyperproliferation leading to luminal filling, we analyzed cyst development in more detail (Figure <ref type="figure" target="#fig_2">3E, 3F</ref>).</s><s>Already at the two-cell stage, apical-basolateral polarization is observed, with F-actin accumulating at the cell-cell interface, associated with the formation of tight junctions that are positive for ZO-1 (Figure <ref type="figure" target="#fig_2">3F</ref>; day 2, -HRG).</s><s>This apical surface is maintained as the cyst develops, specifying the position of the lumen.</s><s>HRG interfered with correct F-actin localization and ZO-1 recruitment, indicating that the initial establishment of polarity and tight junctions were impaired (Figure <ref type="figure" target="#fig_2">3E, 3F</ref>).</s></p><p><s>Biochemical analysis of cell lysates derived from Caco-2 3D cultures grown in the presence of EGF or HRG for three days revealed that EGF induced ErbB1 phosphorylation, whereas HRG induced the phosphorylation of ErbB2 and ErbB3 (Figure <ref type="figure" target="#fig_3">4A</ref>).</s><s>Erk phosphorylation was not maintained after long-term stimulation, whereas Stat3 phosphorylation was slightly elevated in the presence of the ligands.</s><s>Compared to EGF, HRG led to sustained Akt phosphorylation (3-fold) at serine 473 (Figure <ref type="figure" target="#fig_3">4A</ref>), which was comparable to the extent of Akt phosphorylation induced by K-Ras G12V expression in the Caco-2tet cells (Figure <ref type="figure" target="#fig_0">1C</ref>).</s><s>Finally, to prove that ErbB3 was mediating the HRG effect, we knocked down ErbB3 and also ErbB2, as ErbB3 preferentially heterodimerizes with ErbB2, followed by seeding of cells into 3D cultures.</s><s>In the absence of HRG, the receptor knockdowns had little effect on the polarized morphogenesis of the control cultures (siNT) (Figure <ref type="figure" target="#fig_3">4C</ref>, left).</s><s>However, in the presence of HRG, ErbB3 depletion fully restored polarized cyst structure and lumen formation to the level seen in the control.</s><s>Knockdown of ErbB2, however, failed to do so (Figure <ref type="figure" target="#fig_3">4C</ref>, right).</s></p><p><s>To determine whether the distinct morphological phenotypes induced by EGF and HRG could be recapitulated in normal intestinal epithelium, we analyzed these ligands in 3D murine intestinal organoid cultures.</s><s>In accordance with ErbB receptor expression in Caco-2 cells, intestinal epithelium from wildtype and APC min mice expressed ErbB1, ErbB2 and ErbB3, but lacked detectable transcript levels of ErbB4 (Supplementary Figure <ref type="figure" target="#fig_1">S2A</ref>).</s><s>We found that the outgrowth of single intestinal crypts into organoids with a crypt-villus axis was stalled in the absence of ErbB1 ligands.</s><s>EGF supported the outgrowth of organoids with 1-2 crypt domains within 3-4 days, as reported previously <ref type="bibr" target="#b18">[19]</ref>.</s><s>However, when we exchanged EGF for HRG, the crypts formed hyperproliferative organoids with multiple irregularly shaped crypts within 2-3 days (Figure <ref type="figure" target="#fig_4">5A</ref>, 5B).</s><s>Immunofluorescence stainings revealed morphogenetic defects in the presence of HRG, visible as epithelial tufting with partial loss of apical localization of F-actin (Figure <ref type="figure" target="#fig_4">5C</ref>).</s><s>Phospho-protein analysis of the organoids revealed sustained Akt activation by HRG, but not by EGF (Figure <ref type="figure" target="#fig_4">5D</ref>).</s><s>Even high doses of EGF did not upregulate Akt, indicating that the differential signaling induced by EGF and HRG is qualitative and not quantitative.</s><s>Reminiscent of the Caco-2 model (Figure <ref type="figure" target="#fig_3">4B</ref>), long-term stimulation with EGF or HRG suppressed Erk activation (Figure <ref type="figure" target="#fig_4">5D</ref>), probably owing to compensatory feedback mechanisms.</s><s>This analysis of normal tissue provides support that activation of HRG-ErbB3 signaling can contribute to hyperproliferation and tissue disorganization in the intestinal epithelium.</s></p><p><s>Based on our findings, we hypothesized that K-Ras G12V expression in Caco-2 3D cultures may lead to enhanced HRG production.</s><s>Indeed, real-time qPCR analysis revealed that oncogene expression induced HRG1/2 transcript levels (Figure <ref type="figure" target="#fig_5">6A, 6B</ref>).</s><s>We next sought to silence HRG expression prior to the induction of oncogenic Ras.</s><s>In full support of our hypothesis, the combined depletion of HRG1 and HRG2 reduced spheroid size and significantly increased the number of polarized cysts with apical lumens (Figure <ref type="figure" target="#fig_5">6B, 6C</ref>).</s><s>This rescue was also observed by independent siRNAs (Supplementary Figure <ref type="figure" target="#fig_2">S3</ref>) and was comparable to the rescue obtained by pharmacological ErbB inhibition (Figure <ref type="figure" target="#fig_0">1E</ref>) or ErbB3 silencing (Figure <ref type="figure" target="#fig_1">2B</ref>).</s><s>Efficient HRG1/2 knockdown in Ras G12V -expressing cells isolated from the 3D cultures is shown in Figure <ref type="figure" target="#fig_5">6D</ref>.</s><s>To obtain proof that HRG was acting through extracellular ErbB3 binding, we treated Ras G12V -expressing cells with an ErbB3-specific antibody that competes with HRG.</s><s>Importantly, this treatment suppressed proliferation (data not shown) and significantly restored the number of cysts with a normal polarized morphology (Figure <ref type="figure" target="#fig_5">6E, 6F</ref>).</s><s>In conclusion, the hyperproliferation and polarity loss induced by K-Ras G12V in 3D cultures containing 2% FCS in the presence of the indicated growth factors (10 ng/ml) or in 2% FCS as a control (con).</s><s>Three days post seeding cysts were lysed and analyzed by immunoblotting using the indicated antibodies (pErbB2(Tyr1248)).</s><s>Tubulin was detected as a loading control.</s><s>Shown is a representative blot (N=2).</s><s>B. Caco-2 cells were transfected with non-targeting (siNT) and ErbB-receptor specific siRNAs, respectively.</s><s>The next day, cells were seeded into 3D culture in the presence or absence of HRG (10 ng/ml).</s><s>Three days post seeding lumen expansion was induced by CTX.</s><s>The next day, cultures were fixed and stained with DAPI and phalloidin (not shown).</s><s>The percentage of cysts with PSAL was determined (n&gt;50; N=3).</s><s>expression in the 3D Caco-2 model can be ascribed to autocrine HRG-ErbB3 signaling.</s></p><p><s>Compared to human CRC cell lines with wildtype K-Ras genes, the analysis of HRG expression in cell lines harboring activating K-Ras mutations revealed strongly increased HRG2 transcript levels in three out of four cases (SW480, LoVo, HCT116; Supplementary Figure <ref type="figure" target="#fig_3">S4C</ref>).</s><s>This indicates that the upregulation of HRG expression by oncogenic Ras signaling is not restricted to the Caco-2 model system.</s><s>We further found that several ErbB ligands including HRG1 were upregulated in mouse adenoma compared to normal intestinal tissue (Supplementary Figure <ref type="figure" target="#fig_3">S4B</ref>), pointing at the existence of further possible mechanisms activating ErbB receptor signaling during tumor initiation and progression.</s></p><p><s>Finally, by IHC staining of TMAs, we analyzed the expression of ErbB3 in 399 colon tumor samples.</s><s>Staining intensity was quantified in an automated manner and cells with medium or high expression were scored as ErbB3 positive (Figure <ref type="figure" target="#fig_6">7A</ref>).</s><s>Comparison of specimens with less than 20% ErbB3-positive cancer cells with those harboring more than 20% ErbB3-positive cells revealed a significant difference in tumor grade, as determined by chi square trend test (p=0.025).</s><s>Whereas only a single G1 tumor contained more that 20% ErbB3-positive cells (1/27; 4%), 12% of the G2 tumors (35/299) and 19% of the G3 tumors (14/73) displayed medium-to-strong ErbB3 expression in more than 20% of the cells (Figure <ref type="figure" target="#fig_6">7B</ref>).</s><s>This correlation between ErbB3 positivity and increasing tumor grade provides additional support for the contribution of ErbB3 signaling to the dedifferentiation of the intestinal epithelium during tumor progression.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>Using a 3D CRC cell culture model, we here show for the first time that K-Ras G12V induced hyperproliferation and loss of polarized morphogenesis, both of which are hallmarks of tumor progression, engage a HRG/ErbB3 dependent signaling loop.</s><s>In CRC, Ras mutations are preceded by mutations in APC associated with the activation of the WNT pathway and the formation of benign polyps <ref type="bibr" target="#b22">[23]</ref>.</s><s>Considering the frequent cooccurrence of APC and K-Ras mutations, Caco-2 cells are a suitable model for the analysis of the early molecular and cellular changes induced by Ras activation, as these cells harbor an inactivating mutation in APC, but they lack oncogenic alterations of the Ras or Raf genes <ref type="bibr" target="#b20">[21]</ref>.</s></p><p><s>Despite its impaired kinase activity, ErbB3 supports cell survival and mediates drug resistance <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b9">10]</ref>, primarily through the potent induction of the PI3K pathway.</s><s>In breast cancer, the ErbB2-ErbB3 signaling dimer was shown to be essential for tumor formation and maintenance <ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref>.</s><s>Recently, somatic mutations in ErbB3 with transforming potential were reported in colon and gastric cancers, however, these variants were still functionally dependent on ErbB2 <ref type="bibr" target="#b26">[27]</ref>.</s><s>Although ErbB2-ErbB3 is regarded as the most potent ErbB dimer, ErbB3 also dimerizes with ErbB1 and non-ErbB family RTKs such as c-Met <ref type="bibr" target="#b27">[28]</ref>.</s><s>An intestinal-specific ErbB3 knockout mouse model showed that the loss of ErbB3 resulted in loss of the ErbB4 protein, indicative of the formation of cells were seeded into 3D in the presence of dox.</s><s>Three days after seeding, cysts were isolated, RNA was extracted, and HRG1/HRG2 expression was determined by qPCR and normalized to GAPDH (N=2).</s><s>(B-D) Caco-2tet K-Ras G12V cells were transfected with nontargeting (siNT) and a mix of HRG1-and HRG2-specific siRNAs (#1).</s><s>The next day cells were seeded into 3D culture and K-Ras G12V expression was induced with dox one day later.</s><s>B. Cultures were fixed three days later and stained with DAPI (nuclei; blue), anti-aPKC antibody (cyan) and phalloidin (F-actin; red).</s><s>GFP is coexpressed with K-Ras G12V (green).</s><s>Shown are confocal sections of the midplane of representative cysts (scale: 20 μm).</s><s>C. The percentage of cysts with PSAL from (B) was determined (n&gt;70; N=3).</s><s>D. Cysts were isolated three days later and RNA was extracted.</s><s>HRG1/HRG2 expression was determined by qPCR and normalized to GAPDH (N=2).</s><s>E. Cells were seeded into dox-containing 3D culture in the absence (ut) or presence of 100 nM anti-E3-IgG.</s><s>Three days later CTX was added.</s><s>Cultures were fixed the next day and stained with DAPI (nuclei; blue), anti-aPKC antibody (cyan) and phalloidin (F-actin; red).</s><s>GFP is coexpressed with K-Ras G12V (green).</s><s>Shown are confocal sections of the midplane of representative cysts (scale: 20 μm).</s><s>F. The percentage of cysts with PSAL from (E) was determined (n&gt;70; N=3).</s><s>active ErbB3/4 heterodimers <ref type="bibr" target="#b28">[29]</ref>.</s><s>Interestingly, when crossed to Apc Min mice, ErbB3 loss almost completely prevented colonic tumorigenesis, underscoring the important role of ErbB3 signaling in tumor establishment and progression <ref type="bibr" target="#b28">[29]</ref>.</s><s>The promiscuous pairing of ErbB3 with other RTKs may explain why in our experiments the single knockdown of ErbB1 or ErbB2 did not mirror the effects of ErbB3 depletion.</s><s>We also cannot rule out that residual protein in siRNA-treated cells is sufficient for ErbB3 transactivation, in line with disproportionate ErbB2 levels found to efficiently transactivate ErbB3 <ref type="bibr" target="#b29">[30]</ref>.</s><s>The fact that ErbB3 phosphorylation was below the detection limit upon K-Ras G12V induction in Caco-2 cells further indicates that a low number of activated receptors suffices in the cooperative signaling with oncogenic Ras.</s></p><p><s>Mutant K-Ras has been associated with the increased expression and/or shedding of ErbB1 ligands <ref type="bibr" target="#b14">[15,</ref><ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b30">31]</ref>.</s><s>Here we show that K-Ras G12V expression induces the transcriptional activation of HRG1/2, the ablation of which normalized the proliferation and morphology of Caco-2 cells.</s><s>By exogenous addition of HRG to Caco-2 and primary intestinal organoid cultures we confirmed that HRG-induced ErbB3 signaling is not compatible with intestinal epithelial organization.</s><s>Addition of ErbB1 ligands enhanced the proliferation of Caco-2 and organoid cultures but did not interfere with polarized morphogenesis.</s><s>This highlights (i) the independent regulation of proliferation and polarity and (ii) the qualitatively distinct signaling characteristics of the different ErbB ligands.</s></p><p><s>Considering that Akt activation is strongly suppressed in Caco-2 3D cultures compared to 2D monolayers <ref type="bibr" target="#b21">[22]</ref>, the elevated pAkt levels downstream of ErbB3 may contribute to the HRG-induced proliferation and/or polarity loss.</s><s>However, in a previous report, the stable expression of activated PI3K in Caco-2 cells did not perturb 3D morphogenesis and PI3K inhibition failed to rescue the morphology or size of Caco-2 spheroids stably expressing mutant Ras <ref type="bibr" target="#b20">[21]</ref>.</s><s>This suggests that further signaling pathways besides PI3K are required to stimulate proliferation and disrupt epithelial morphogenesis in Caco-2 Ras G12V cells.</s><s>For example, in pancreatic adenocarcinoma, both PI3K and Stat3 activation downstream of ErbB1 were found to be essential for Ras-induced transformation <ref type="bibr" target="#b31">[32]</ref>.</s><s>In Madin-Darby canine kidney cells the specific inhibition of the aPKC isoform PKCiota partially restored the non-polar spheroid morphogenesis observed in cells overexpressing activated H-Ras or ErbB2 <ref type="bibr" target="#b32">[33]</ref>.</s><s>In epithelial cells, spatially controlled aPKC activity is necessary for the establishment and maintenance of apicobasal polarity.</s><s>Considering that the recruitment of the Par6-aPKC complex to activated ErbB2 in the MCF10A breast epithelial acini model was shown to mediate disruption of epithelial polarity <ref type="bibr" target="#b33">[34]</ref>, it is tempting to speculate that HRG-activated ErbB3 in intestinal cells may operate through a similar mechanism.</s></p><p><s>Increased expression of ErbB3 in CRC was found to correlate with poorer overall survival and disease stage <ref type="bibr" target="#b34">[35,</ref><ref type="bibr" target="#b35">36]</ref> and as revealed in this study with higher tumor grade.</s><s>However, there is still little known about the expression of ErbB3 and the ErbB ligands in the different CRC subtypes.</s><s>Irrespective of cancer-associated mutations in K-Ras, aberrant HRG production by the stromal compartment could also impair the integrity of the intestinal epithelium.</s><s>Apart from driving proliferation, HRG is a stimulator of cell migration and invasion <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b11">12]</ref>.</s><s>In future studies it will be important to analyze the signaling profiles and transcriptional programs activated in the epithelial cells responding to this ligand.</s></p><p><s>Currently, several ErbB3-directed antibodies targeting the extracellular domain of the receptor are in clinical development <ref type="bibr" target="#b36">[37]</ref>.</s><s>A subset of CRC patients with Ras wildtype tumors fails to show an initial response to anti-ErbB1 therapy, whereas those that do respond routinely develop resistance, often by selection of Ras mutant clones.</s><s>In such patients elevated circulating HRG levels were associated with both de novo and acquired resistance to Cetuximab therapy <ref type="bibr" target="#b37">[38]</ref>.</s><s>Several reports describe the upregulation of ErbB3 as an evasion strategy to RTK inhibition <ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b39">[40]</ref><ref type="bibr" target="#b40">[41]</ref> and pharmacologic MEK inhibition downstream of mutant Ras also unleashes feedbacks at the level of RTKs, including ErbB3 <ref type="bibr" target="#b41">[42,</ref><ref type="bibr" target="#b42">43]</ref>.</s><s>Thus, combination treatments involving ErbB3 may be particularly effective for the treatment of Ras mutant CRC and may also prevent HRG-mediated resistance in Ras wildtype CRC.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MATERIALS AND METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Antibodies and reagents</head><p><s>Antibodies used were monoclonal rabbit anti-pEGFR (Y1068), polyclonal rabbit anti-pERK (T202/ Y204), monoclonal rabbit pErbB2 (Tyr1221/1222), polyclonal rabbit anti-pErbB2 (Tyr1248), monoclonal rabbit pErbB3 (Tyr1289), monoclonal mouse anti-ERK, monoclonal rabbit anti-pAKT (Thr308), monoclonal mouse anti-AKT (pan), monoclonal mouse anti-pAKT (Ser473), monoclonal mouse anti-Stat3 (124H6), monoclonal rabbit anti-pStat3 (Tyr705) (D3A7) XP ® (all from Cell Signaling, Danvers, MA, USA), polyclonal rabbit ZO-1 antibody (Invitrogen, Carlsbad, CA, USA), monoclonal mouse anti E-cadherin (BD, CA, SanJose, USA), monoclonal mouse anti-ErbB1 (Thermo Scientific, Fremont, MA, USA), polyclonal rabbit anti-aPKC (zeta), polyclonal rabbit anti-ErbB2, polyclonal rabbit anti-ErbB3 (all from Santa Cruz Biotechnology, Dallas, TX, USA) and monoclonal mouse anti-alpha-tubulin (Sigma-Aldrich, St Louis, MO, USA).</s><s>The ErbB3-blocking antibody anti-E3-IgG was generated in-house and will be described in detail elsewhere (Schmitt et al., in preparation).</s><s>HRP-labeled secondary anti-mouse and anti-rabbit IgG antibodies were from GE Healthcare (Buckinghamshire, UK).</s><s>Alexa Fluor 488-and 546-labeled secondary antimouse and anti-rabbit IgG antibodies and Alexa Fluor 633-labeled phalloidin were from Invitrogen.</s><s>DAPI was from Sigma-Aldrich.</s><s>EGF was from R&amp;D Systems Inc. (Minneapolis, MN, USA); TGF-α, HB-EGF, HRG were from PeproTech (Hamburg, Germany), and AREG, EREG, BTC were from ImmunoTools (Friesoythe, Germany).</s><s>The pan-ErbB inhibitor AZD8931 (Sapitinib) was Absource Diagnostics (Munich, Germany).</s><s>The ErbB2 Inhibitor II (#324732) was from Calbiochem (Darmstadt, Germany).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cell lines and 3D cell culture</head><p><s>Caco-2 cells were obtained from Interlab Cell Line Collection (Genova, Italy) in 2012 and reauthenticated by SNP analysis in 2016 (Multiplexion, Immenstadt, Germany).</s><s>Caco-2tet cells, stably expressing the doxycycline-inducible system components rtTA and rtTS <ref type="bibr" target="#b43">[44]</ref> and Caco-2tet K-Ras G12V cells were described previously <ref type="bibr" target="#b21">[22]</ref>.</s><s>The corresponding parental cells were authenticated in 2014 (see above).</s><s>SW480, LS174T, Colo-320DM and Difi cells were obtained from the Institute of Clinical Pharmacology (Stuttgart, Germany), Lovo and HCT116 cells were from Interlab Cell Line Collection (Genova, Italy).</s><s>Caco-2, SW480, LS174T, Colo-320DM, Difi, Lovo and HCT116 cells were cultured in RPMI 1640 (Invitrogen) and Caco-2tet cells in DMEM (Invitrogen), both supplemented with 10% FCS (PAA Laboratories, Cölbe, Germany).</s><s>Cell lines were incubated in a humidified atmosphere of 5% CO 2 at 37 °C.</s><s>For growth in 3D, cells were seeded on a bed of growth factor reduced matrigel (BD) and PureCol ® -S collagen (Advanced Biomatrix, San Diego, CA, USA) (1:1) and overlaid with growth medium containing 2% matrigel.</s><s>Lumen expansion was induced by addition of 100 ng/ml Choleratoxin (CTX; Sigma Aldrich) at day 3 post seeding.</s><s>Transgene expression in the Caco-2tet cells was induced by 2 μg/ml doxycycline (dox; Merck, Darmstadt, Germany).</s><s>For growth factor dependent assays cells were grown in medium containing 2% FCS plus 10 ng/ml growth factor.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MTT assays</head><p><s>Cells were seeded into matrigel/collagencoated 96-well plates (100 μl medium containing 2% matrigel).</s><s>Viability was determined by addition of 10 μl 3-(4,5-dimethylthiazol-2yl-)2,5-diphenyl tetrazolium (MTT; Roth, Karlsruhe, Germany) solution (5 mg/ml) followed by incubation for 3 h at 37 °C.</s><s>Cells were then lysed by addition of 100 μl 50% dimethylformamide containing 10% SDS and absorbance was measured at 570 nm using the multimode reader Infinite ® 200 PRO (Tecan, Männedorf, Switzerland).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>siRNAs</head><p><s>As non-targeting negative controls (siNT) ON-TARGETplus ® non-targeting control pool (Dharmacon) or Silencer ® Select Negative Control#2 (Invitrogen) were used.</s><s>In all cases, two independent siRNAs were used: siErbB1 refers to siGenome SMARTpool EGFR (M-003114-03-0005) from Dharmacon; siErbBR1#2 refers to Silencer ® Select ErbB1 (s565) from Invitrogen); siErbB2 refers to a single duplex with the sense sequence: 5'-GGACGAAUUCUGCACAAUG-3', from Eurofins MWG Operon; siErbB2#2 refers to Silencer ® Select ErbB2 (s612) from Invitrogen; siErbB3 refers to siGenome SMARTpool ErbB3 (M-003127-03-0005) from Dharmacon; siErbBR3#2 refers to Silencer ® Select ErbB3 (s4779) from Invitrogen); siHRG1#1 refers to Silencer ® Select NRG1 (s230508), siHRG1#2 refers to Silencer ® Select NRG1 (s230507), siHRG2#1 refers to Silencer ® Select NRG2 (s18322) and siHRG2#2 refers to Silencer ® Select NRG2 (s18321) (all from Invitrogen).</s><s>Cells were transfected with siRNA using DharmaFECT1 (Dharmacon, Lafayette, CO, USA) according to manufacturer's instructions.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Western blotting</head><p><s>Cells were lysed in RIPA buffer (50 mM Tris (pH 7.5), 150 mM NaCl, 1% Triton-X 100, 0.5 sodium deoxycholate, 0.1% SDS, 1 mM sodium orthovanadate, 10 mM sodium fluoride and 20 mM β-glycerophosphate plus protease inhibitors (Roche, Basel, Switzerland).</s><s>For lysates from 3D cultures, cells were cultured on pure matrigel without collagen.</s><s>Spheroids were isolated after 4 days by dissolving the matrigel in ice cold Cell Recovery Solution (BD).</s><s>After centrifugation the spheroids were lysed in RIPA buffer.</s><s>Lysates were clarified by centrifugation.</s><s>Equal amounts of protein were separated by SDS-PAGE (NuPAGE ® Novex Bis-Tris Gel; Invitrogen) and transferred to nitrocellulose membrane (iBlot ® Gel Transfer Stacks; Invitrogen).</s><s>Alternatively lysates were loaded on 10% polyacrylamide gels and transferred to polyvinylidene difluoride membranes (Roth).</s><s>Membranes were blocked with 0.5% blocking reagent (Roche) in PBS containing 0.1% Tween-20 and incubated with primary antibodies, followed by HRPconjugated secondary antibodies.</s><s>Visualization was done with ECL detection system (Pierce, Rockford, IL, USA).</s><s>Alternatively detection was done with IR-labled secondary antibodies IRDye 800 CW goat anti-mouse IgG (Licor Biotechnology, Bad-Homburg, Germany) and IRDye 680 LT goat anti-rabbit IgG (Licor Biotechnology).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Quantitative PCR</head><p><s>Total RNA was isolated from cells using the RNeasy ® Plus Mini Kit (Qiagen, Foster City, CA, USA) according to the manufacturer's protocol.</s><s>For 2D cell cultures, 2x10 5 to 1x10 6 cells were lysed with RLT buffer according to the manufacturer's protocol.</s><s>For 3D culture, 4x10 5 cells were seeded in 12-well plates on matrigel, as described for protein extraction.</s><s>Pelleted spheroids were lysed in 350 μl RLT buffer according to the manufacturer's protocol.</s><s>RNA samples were quantified using a Nanophotometer (Implen, Munich, Germany) at OD 260/280 nm.</s><s>Q-PCR was performed with QuantiTect Primer Assays ® for SYBR ® Green-based expression analysis (Qiagen) using a Cfx96 device (Biorad) according to the manufacture's protocol for one-step RT-PCR.</s><s>Primers used were Hs_NRG1_1_SG QuantiTect Primer Assay, Hs_NRG2_1_SG QuantiTect Primer Assay and Hs_GAPDH_2_SG QuantiTect Primer Assay (all Qiagen).</s><s>Changes in the relative expression level were calculated using the 2-ΔΔCt method (Biorad CFX manager software 3.1.).</s><s>GAPDH was used as the endogenous control gene for normalization.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunofluorescence microscopy</head><p><s>Cells grown in 3D on matrigel/collagen coated 8-well glass chamber slides (BD) were fixed and stained as described <ref type="bibr" target="#b21">[22]</ref>.</s><s>To determine the number of cysts with a 'predominant single apical lumen' (PSAL) <ref type="bibr" target="#b32">[33]</ref>, spheroids were analyzed in terms of roundness, cell-free lumen formation and F-actin staining of the apical surface.</s><s>Round spheroids with a single-cell layer around a hollow lumen and distinct F-actin staining were scored as normal, cysts lacking at least two of these features were scored as abnormal.</s><s>For organoid stainings, organoids were washed with PBS to remove matrigel and fixed with 4% PFA, followed by immunostaining as described in <ref type="bibr" target="#b21">[22]</ref>.</s><s>Organoids were imaged in PBS on a cell observer spinning disc system (Zeiss) equipped with an oil immersion objective LD LCI Plan-Apochromat 25x/0.8</s><s>Imm Corr DIC M27 and an Axiocam 503 mono CCD camera using 405, 561 and 638 nm excitation.</s><s>Images were processed with the ZEN software (Zeiss).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Intestinal organoid cultures and protein analysis</head><p><s>Organoids of the murine small intestine were cultured as described <ref type="bibr" target="#b44">[45]</ref>.</s><s>For outgrowth analysis, organoids were washed in PBS, disaggregated into single crypts and embedded in growth factor-reduced matrigel and crypt culture medium containing Noggin (Peprotech, Rocky Hill, NJ, USA) and R-spondin (produced as described in <ref type="bibr" target="#b45">[46]</ref>).</s><s>Outgrowth in the absence or presence of EGF/HRG was monitored in 24 h intervals.</s><s>Proteins were analyzed by a WES capillary Western system (ProteinSimple), using the 12-230 kDa Master Kit α-Rabbit-HRP and pAkt T308 and pErk1/2 T202/Y204 antibodies (1:50, Cell Signalling) and α-vinculin (1:30, Cell Signalling) for normalization.</s><s>In short, organoids were washed in ice-cold PBS by centrifugation, lysed in 25 μl M-PER buffer (Pierce #78501) supplemented with PhosSTOP and Complete EDTA-free phosphatase inhibitor cocktails (Roche) for 30 min on ice, frozen at -80°C, thawed on ice, and sonified (Bioruptor/diagenode, 5 minutes at "H", interval 0,5).</s><s>Lysates were spun for 10 min at 4°C in a tabletop centrifuge, and protein was measured by BCA assay (Pierce).</s><s>Lysates were used at 0.5 and 0.2 μg/μl for pAkt and pErk, respectively, according to the manufacturer's protocol.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Tissue microarrays (TMAs) and immunohistochemical (IHC) analysis</head><p><s>Formalin-fixed paraffin-embedded (FFPE) colon cancer samples of 399 patients treated at the Robert Bosch Hospital were used for IHC analysis.</s><s>Patient and clinicopathological data of colon tumors are given in Supplementary Table <ref type="table">S1</ref>.</s><s>The study was approved by the ethics committee in Tübingen.</s><s>TMAs were prepared using the Manual Tissue Microarrayer MTA-1 (Beecher Instruments Inc, Sun Prairie, Wisconsin, USA) by punching three tissue cylinders (diameter: 600 μm) from each FFPE sample.</s><s>For IHC analysis, TMAs were cut into 3 μm sections, incubated in EDTA buffer, pH 8.0 (30 min, steam heater).</s><s>Staining for ErbB3 was done using anti-ErbB3/HER3, clone SP71 from Biomol <ref type="bibr" target="#b46">[47]</ref> and the Dako envision Kit (Dako, Hamburg, Germany).</s><s>The antibody was diluted 1:100 in Dako antibody diluent.</s><s>Validation was done using duodenum as a positive control; isotype-specific immunoglobulin was used as a negative control (Supplementary Figure <ref type="figure" target="#fig_4">S5</ref>).</s><s>Counterstaining was done using Papanicolaou's solution 1A Harris (Merck Millipore; Darmstadt; Germany).</s><s>Slides were digitalized (SCN400 slide scanner; 20x objective; Leica Microsystems, Mannheim, Germany) and analyzed by a custom-made solution in the Tissue Studio software (Definiens, München, Germany), which was validated manually by two independent observers <ref type="bibr" target="#b47">[48]</ref>.</s><s>For each of the three cores of one patient specimen the percentage of cancer cells showing no, weak, moderate, and strong staining intensity was determined and averaged.</s><s>Cores with less than 100 cancer cells were excluded from the analysis.</s><s>For correlation analysis of ErbB3 expression and tumor grade, the cut-off for ErbB3 positivity was set between low and medium staining intensity.</s><s>Tumor grades were determined as described <ref type="bibr" target="#b48">[49]</ref>.</s><s>For statistical analysis chi square trend test was performed using R (R Foundation for Statistical Computing, Vienna, Austria) with additional packages coin-1.0-24</s><s><ref type="bibr" target="#b49">[50]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>Data are expressed as mean ± S.E.M.; 'n' refers to the number of samples/experiment, N' to the number of independent experiments.</s><s>Statistical significance was evaluated by t-test and one-way ANOVA followed by Tukey's post-test (GraphPad Prism version 4.03; GraphPad Software Inc., La Jolla, CA).</s><s>p-values below 0.05 were considered significant (*p &lt; 0.05; ** p &lt; 0.01; *** p &lt; 0.001; ns, p &gt; 0.05).</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 :</head><label>1</label><figDesc><div><p><s>Figure 1: ErbB receptor inhibition restores aberrant morphogenesis of Caco-2 K-Ras G12V cells in 3D culture.</s><s>A. Caco-2tet K-Ras G12V cells were seeded into 3D cultures in the absence or presence of dox.</s><s>Three days post seeding lumen expansion was induced by CTX.</s><s>Cultures were fixed two days later and stained with DAPI (nuclei; blue) and phalloidin (F-actin; red).</s><s>GFP is co-expressed with K-Ras G12V (green).</s><s>Shown are confocal sections of the midplane of representative cysts, nuclei are numbered in white (scale: 20 μm).</s><s>B.The percentage of cysts with PSAL from (A) was determined (n&gt;70; N=3).</s><s>C. The number of nuclei in the midplane of cysts from (A) was counted (n=25; N=3).</s><s>D. Caco-2tet K-Ras G12V cells were seeded into 3D cultures.</s><s>One day post seeding K-Ras G12V -expression was induced by dox and cultures were left untreated or treated with 200 nM AZD8931.</s><s>Two days later CTX was added.</s><s>Cultures were fixed the next day and stained with DAPI (nuclei; blue) and phalloidin (F-actin; red).</s><s>GFP is co-expressed with K-Ras G12V (green).</s><s>Shown are confocal sections of the midplane of representative cysts (scale: 20 μm).</s><s>E. The percentage of cysts with PSAL from (D) was determined (n&gt;60; N=3).</s><s>F. The number of nuclei in the midplane of cysts from (D) was counted (n=25; N=3) G. Caco-2tet K-Ras G12V cells were seeded into 3D cultures.</s><s>One day post seeding K-Ras G12V expression was induced by dox and cultures were left untreated or treated with 200 nM AZD8931.</s><s>Lysates were generated four days after seeding and analyzed by immunoblotting using the indicated antibodies (pErbB2(Tyr1248)).</s><s>Tubulin was detected as a loading control.</s><s>A representative blot is shown (N=3).</s></p></div></figDesc><graphic coords="3,95.45,160.07,434.76,409.75" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 :</head><label>2</label><figDesc><div><p><s>Figure 2: ErbB3 knockdown rescues hyperproliferation and polarized morphogenesis of Caco-2 cells expressing oncogenic K-Ras. A. Caco-2tet K-Ras G12V cells were transfected with non-targeting (siNT) and ErbB receptor-specific siRNAs,respectively.</s><s>The next day cells were seeded into 3D culture.</s><s>One day post seeding K-Ras G12V expression was induced with dox.</s><s>Two days later CTX was added.</s><s>Cultures were fixed the next day and stained with DAPI (nuclei; blue), anti-aPKC antibody (cyan) and phalloidin (F-actin; red).</s><s>GFP is co-expressed with K-Ras G12V (green).</s><s>Shown are confocal sections of the midplane of representative cysts (scale: 20 μm).</s><s>B. The percentage of cysts with PSAL from (A) was determined (n&gt;70; N=3).</s><s>C. The number of nuclei in the midplane of cysts from (A) was counted (n=25; N=3).</s><s>D. Two days after gene silencing, lysates were generated and analyzed by immunoblotting using the indicated antibodies.</s><s>Tubulin was detected as a loading control.</s><s>Specific bands are marked by arrowheads.</s></p></div></figDesc><graphic coords="4,84.93,286.03,443.15,335.47" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3 :</head><label>3</label><figDesc><div><p><s>Figure 3: Heregulin impairs apical-basolateral polarity and lumenogenesis of Caco-2 cysts.</s><s>A. Caco-2 cells were grown in 3D cultures containing 2% FCS in the presence of the indicated growth factors (10 ng/ml) or in 2% FCS as a control (con).</s><s>3D cultures were analyzed by MTT assay at day 6 (N=3).(B+C)</s><s>Cells were grown as described in (A).</s><s>Three days later CTX was added.</s><s>Cultures were fixed the next day and stained with DAPI (nuclei; blue) and phalloidin (F-actin; red).</s><s>B. The percentage of cysts with PSAL was determined (n&gt;70; N=3).</s><s>C. Shown are confocal sections of the midplane of representative cysts (scale: 20 μm).</s><s>D. Caco-2 cells grown in the presence or absence of HRG were stained with anti-E-cadherin antibody (green), anti-aPKC antibody (cyan) and DAPI (nuclei; blue).</s><s>(E+F) Caco-2 cells were grown in 3D cultures containing 10% FCS in the presence or absence of HRG (10 ng/ml).</s><s>Cultures were fixed at the indicated days after seeding, and stained with DAPI (nuclei; blue) and phalloidin (F-actin; red).</s><s>At day three, CTX was added.</s><s>E. The percentage of cysts with PSAL was determined (n&gt;25; N=2).</s><s>F. Shown are confocal sections of the midplane of representative cysts (scale: 20 μm).</s></p></div></figDesc><graphic coords="5,95.52,239.00,421.96,372.35" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 4 :</head><label>4</label><figDesc><div><p><s>Figure 4: HRG-induced ErbB3 signaling impairs polarized morphogenesis of Caco-2 cells.</s><s>A. Caco-2 cells were grown</s></p></div></figDesc><graphic coords="6,93.69,455.16,425.62,179.72" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 5 :</head><label>5</label><figDesc><div><p><s>Figure 5: HRG triggers hyperproliferation and disrupts the architecture of intestinal organoids.</s><s>A. Representative photographic series of intestinal crypts developing in the absence (con) or presence of 10 ng/ml EGF or HRG in 3D organoid culture.</s><s>White arrowheads on day 3 indicate crypt domains.</s><s>(Scale: 100 μm).</s><s>B. Quantification of crypt domains per organoid on day three (N=3).</s><s>C. Organoids were fixed on day 1 and stained with anti-E-cadherin antibody (green), phalloidin (F-actin; red) and DAPI (nuclei; blue) (scale: 50 μm).</s><s>D. Capillary phospho-protein analysis of untreated organoids (con) and treated with EGF or HRG (N=2).</s></p></div></figDesc><graphic coords="7,95.48,208.00,422.03,448.45" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 6 :</head><label>6</label><figDesc><div><p><s>Figure 6: HRG depletion restores lumen formation in oncogenic K-Ras G12V expressing Caco-2 cells.</s><s>A. Caco-2tet K-Ras G12V</s></p></div></figDesc><graphic coords="8,95.52,326.00,421.97,254.32" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Figure 7 :</head><label>7</label><figDesc><div><p><s>Figure 7: ErbB3 expression correlates with tumor grade in primary colon cancers.</s><s>A. ErbB3 staining of two representative specimens (left) and computer-based quantification of staining intensity by Definiens software (right).</s><s>Top: ErbB3 negative; bottom: ErbB3 positive.</s><s>(Scale: 100 μm).</s><s>B. Total numbers and percentages of G1, G2 and G3 specimens with more than 20% ErbB3-positive cells are listed.</s></p></div></figDesc><graphic coords="9,166.05,402.51,280.90,275.25" type="bitmap" /></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">www.impactjournals.com/oncotarget</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONFLICTS OF INTEREST</head><p><s>The authors have no conflicts of interest to declare.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>GRANT SUPPORT</head><p><s>This work was funded by the Bundesministerium für Bildung und Forschung (BMBF) e:Bio grant 'PREDICT' (MAO, RK, MS) and OncoPATH (CS, MM), the German Cancer Consortium DKTK (CS) and the Robert Bosch Foundation (Stuttgart, Germany).</s><s>MAO is funded by the Heisenberg program of the Deutsche Forschungsgemeinschaft (DFG).</s></p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Genetic prognostic and predictive markers in colorectal cancer</title>
		<author>
			<persName><forename type="first">A</forename><surname>Walther</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Johnstone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Swanton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Midgley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Tomlinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kerr</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Cancer</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="489" to="499" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">KRAS mutant colorectal tumors: Past and present</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Brand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Wheeler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Small GTPases</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="34" to="39" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Barbacid</surname></persName>
		</author>
		<author>
			<persName><surname>Genes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annu Rev Biochem</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="779" to="827" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Brand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Iida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Wheeler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Biol Ther</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="777" to="792" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Implications for KRAS status and EGFRtargeted therapies in metastatic CRC</title>
		<author>
			<persName><forename type="first">N</forename><surname>Normanno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tejpar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Morgillo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Luca A De, Van Cutsem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ciardiello</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="519" to="527" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Untangling the ErbB signalling network</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Yarden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">X</forename><surname>Sliwkowski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Mol Cell Biol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="127" to="137" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors</title>
		<author>
			<persName><forename type="first">Tpj</forename><surname>Garrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Mckern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Elleman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Adams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">O</forename><surname>Lovrecz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kofler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Jorissen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Nice</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Burgess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Ward</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cell</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="495" to="505" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">N</forename><surname>Amin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Campbell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Moasser</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Cell Dev Biol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="944" to="950" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Guy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Platko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Cantley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Cerione</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Carraway</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="8132" to="8136" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Novel anticancer targets: revisiting ERBB2 and discovering ERBB3</title>
		<author>
			<persName><forename type="first">J</forename><surname>Baselga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Swain</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Cancer</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="463" to="475" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Role of heregulin in human cancer</title>
		<author>
			<persName><forename type="first">M</forename><surname>Breuleux</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Mol Life Sci</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="2358" to="2377" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Neuregulins and cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Montero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Rodríguez-Barrueco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ocaña</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Díaz-Rodríguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Esparís-Ogando</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pandiella</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="3237" to="3241" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Segregation of receptor and ligand regulates activation of epithelial growth factor receptor</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Vermeer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Einwalter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">O</forename><surname>Moninger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Rokhlina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Kern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zabner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Welsh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">422</biblScope>
			<biblScope unit="page" from="322" to="326" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Tumor metastasis: molecular insights and evolving paradigms</title>
		<author>
			<persName><forename type="first">S</forename><surname>Valastyan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Weinberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">147</biblScope>
			<biblScope unit="page" from="275" to="292" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Gangarosa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Sizemore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Graves-Deal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Oldham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Der</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Coffey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">272</biblScope>
			<biblScope unit="page" from="18926" to="18931" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Stimulated PI3K-AKT signaling mediated through ligand or radiationinduced EGFR depends indirectly, but not directly, on constitutive K-Ras activity</title>
		<author>
			<persName><forename type="first">M</forename><surname>Toulany</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Rodemann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cancer Res</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="863" to="872" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Modelling glandular epithelial cancers in three-dimensional cultures</title>
		<author>
			<persName><forename type="first">J</forename><surname>Debnath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Brugge</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Cancer</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="675" to="688" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Three-dimensional culture models of normal and malignant breast epithelial cells</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">Y</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Kenny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Bissell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Methods</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="359" to="365" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications</title>
		<author>
			<persName><forename type="first">T</forename><surname>Sato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Clevers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">340</biblScope>
			<biblScope unit="page" from="1190" to="1194" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Cdc42 controls spindle orientation to position the apical surface during epithelial morphogenesis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Jaffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kaji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Durgan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Journal of Cell Biology</title>
		<imprint>
			<biblScope unit="volume">183</biblScope>
			<biblScope unit="page" from="625" to="633" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Ras and B-Raf oncogenes inhibit colon epithelial polarity establishment through up-regulation of c-myc</title>
		<author>
			<persName><forename type="first">K</forename><surname>Magudia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lahoz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hall</surname></persName>
		</author>
		<author>
			<persName><surname>K-</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Journal of Cell Biology</title>
		<imprint>
			<biblScope unit="volume">198</biblScope>
			<biblScope unit="page" from="185" to="194" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">EGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistance in KRAS mutant colorectal cancer cells</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Möller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Siegemund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Beyes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Herr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lecis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Delia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kontermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Brummer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Pfizenmaier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Olayioye</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">e107165</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Genetic alterations in colorectal cancer</title>
		<author>
			<persName><forename type="first">T</forename><surname>Armaghany</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Chu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mills</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastrointest Cancer Res</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="19" to="27" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation</title>
		<author>
			<persName><forename type="first">T</forename><surname>Holbro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Beerli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Koziczak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Barbas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Hynes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="8933" to="8938" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Lee-Hoeflich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Crocker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Munroe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P</forename><surname>Hoeflich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">X</forename><surname>Sliwkowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Stern</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Research</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="5878" to="5887" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Vaught</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Stanford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Hicks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Wheeler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rinehart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Sánchez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Koland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Muller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Arteaga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Cook</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Research</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="2672" to="2682" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Oncogenic ERBB3 mutations in human cancers</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Jaiswal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Kljavin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>Stawiski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Parikh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Durinck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chaudhuri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Pujara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Guillory</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Edgar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Janakiraman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Scholz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Bowman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Cell</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="603" to="617" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Engelman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Zejnullahu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mitsudomi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hyland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">O</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Lindeman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Christensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kosaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Holmes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Rogers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">316</biblScope>
			<biblScope unit="page" from="1039" to="1043" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium</title>
		<author>
			<persName><forename type="first">D</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pannicia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Kurie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Threadgill</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="2702" to="2713" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">erbB3 is an active tyrosine kinase capable of homo-and heterointeractions</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Steinkamp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Low-Nam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yang</forename><forename type="middle">S</forename><surname>Lidke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Lidke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cell Biol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="965" to="977" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Oncogenic Kras Promotes Chemotherapy-Induced Growth Factor Shedding via ADAM17 // Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17</title>
		<author>
			<persName><forename type="first">S</forename><surname>Van Schaeybroeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Kyula</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fenton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Fenning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sasazuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Shirasawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Longley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Johnston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Van Schaeybroeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Kyula</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fenton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Fenning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sasazuki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Research</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="1071" to="1080" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma</title>
		<author>
			<persName><forename type="first">C</forename><surname>Navas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Hernández-Porras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Schuhmacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sibilia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Guerra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Barbacid</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Cell</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="318" to="330" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Regulation of polarized morphogenesis by protein kinase C iota in oncogenic epithelial spheroids</title>
		<author>
			<persName><forename type="first">M</forename><surname>Linch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sanz-Garcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rosse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Riou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Peel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Madsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sahai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Downward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Khwaja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dillon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Roffey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ajm</forename><surname>Cameron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Parker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Carcinogenesis</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="396" to="406" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Par6-aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control</title>
		<author>
			<persName><forename type="first">V</forename><surname>Aranda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Haire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Nolan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Calarco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Z</forename><surname>Rosenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Fawcett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pawson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Muthuswamy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Cell Biol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="1235" to="1245" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer</title>
		<author>
			<persName><forename type="first">A</forename><surname>Beji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Horst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kirchner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ullrich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="956" to="968" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Increasing potential of HER3 signaling in colon cancer progression and therapy</title>
		<author>
			<persName><forename type="first">C</forename><surname>Gespach</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="917" to="919" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Molecular pathways: HER3 targeted therapy</title>
		<author>
			<persName><forename type="first">K</forename><surname>Gala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chandarlapaty</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1410" to="1416" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab</title>
		<author>
			<persName><forename type="first">K</forename><surname>Yonesaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Zejnullahu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Okamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Satoh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cappuzzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Souglakos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ercan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rogers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Roncalli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Takeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Fujisaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Philips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Shimizu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci Transl Med</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="99" to="86" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Garrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Olivares</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rinehart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">D</forename><surname>Granja-Ingram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Sánchez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chakrabarty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dave</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Cook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Pao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mckinely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Manning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Arteaga</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page" from="5021" to="5026" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">V</forename><surname>Sergina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rausch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Blair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Shokat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Moasser</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">445</biblScope>
			<biblScope unit="page" from="437" to="441" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Wheeler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Kruser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Nechrebecki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Armstrong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Benavente</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Gondi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Harari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="3944" to="3956" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3</title>
		<author>
			<persName><forename type="first">C</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hobor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bertotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Zecchin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Galimi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cottino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Prahallad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Grernrum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tzani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schlicker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lfa</forename><surname>Wessels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">F</forename><surname>Smit</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Rep</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="86" to="93" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Turke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Costa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Cook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Arteaga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Asara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Engelman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Research</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="3228" to="3237" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling</title>
		<author>
			<persName><forename type="first">M</forename><surname>Röring</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Herr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Fiala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Heilmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Braun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Eisenhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Halbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Capper</surname></persName>
		</author>
		<author>
			<persName><surname>Deimling A Von</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Schamel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">N</forename><surname>Saunders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Brummer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">EMBO J</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="2629" to="2647" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett&apos;s epithelium</title>
		<author>
			<persName><forename type="first">T</forename><surname>Sato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Stange</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ferrante</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rgj</forename><surname>Vries</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Van Es</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Van Den Brink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Van Houdt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pronk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Van Gorp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Siersema</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Clevers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="page" from="1762" to="1772" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Sustained in vitro intestinal epithelial culture within a Wnt-dependent stem cell niche</title>
		<author>
			<persName><forename type="first">A</forename><surname>Ootani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sangiorgi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">T</forename><surname>Ho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ueno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Toda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sugihara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Fujimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">L</forename><surname>Weissman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Capecchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Kuo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="701" to="706" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lyu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Edgerton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Thor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Liu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Breast Cancer Res</title>
		<imprint>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">MCT4 surpasses the prognostic relevance of the ancillary protein CD147 in clear cell renal cell carcinoma</title>
		<author>
			<persName><forename type="first">P</forename><surname>Fisel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Stühler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bedke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Winter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rausch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hennenlotter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Nies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Stenzl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Scharpf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fend</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kruck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schwab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Schaeffeler</surname></persName>
		</author>
		<idno type="DOI">10.18632/oncotarget.5593</idno>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="30615" to="30627" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival</title>
		<author>
			<persName><forename type="first">R</forename><surname>Fux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schwab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Thon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Gleiter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Fritz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="4754" to="4760" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<monogr>
		<title level="m" type="main">A Lego System for Conditional Inference</title>
		<author>
			<persName><forename type="first">T</forename><surname>Hothorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hornik</surname></persName>
		</author>
		<author>
			<persName><surname>Van De Wiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zeileis</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
